{"disease":{"id":"well-differentiated-neuroendocrine-carcinoma","name":"well differentiated neuroendocrine carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02955069","title":"Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03616431","title":"Pancreatic Cancer Dietary Assessment Study","phase":"","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"The Christie NHS Foundation Trust","has_results":false},{"nct_id":"NCT05746208","title":"Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":29,"lead_sponsor_name":"University of California, San Francisco","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}